Longevity
PNC27
CANCER RESEARCH ONLY: p53-derived peptide inducing tumor cell necrosis through HDM-2 interaction; no human clinical trials, and no longevity or anti-aging protocol exists.
Preclinical oncology research only Longevity
- Full name
- PNC-27; p53-derived HDM-2-targeting membrane-disrupting peptide
- Also known as
- PNC-27
- Regulatory status
- Preclinical oncology research only; no human trials
Origin
A 32-residue chimeric peptide fusing a p53-derived HDM-2 (MDM2) binding domain to a cell-penetrating penetratin leader sequence, built to target the p53-MDM2 interaction specifically in cancer cells that overexpress membrane-associated HDM-2.
Mechanism
Binds membrane-associated HDM-2 with high affinity, forming complexes that dimerize and create transmembrane pores. This causes rapid necrosis selectively in cells expressing surface HDM-2, a feature of transformed, not normal, cells.
Research summary
Evidence
Shows selective tumor cell killing in multiple cancer xenograft mouse models (pancreatic, leukemia, colon, ovarian) and ex vivo patient-derived samples. NO human clinical trials exist or are registered. All data are preclinical mouse xenograft or ex vivo findings, not evidence of human safety or efficacy.
Evidence tier: Preclinical oncology research only — see the methodology note for how this is assessed.
Citations
- Anti-Cancer Peptide PNC-27 Kills Cancer Cells by Unique Interactions with Plasma Membrane-Bound hdm-2 and with Mitochondrial Membranes Causing Mitochondrial Disruption — Krzesaj et al. 2024
- PNC-27, a Chimeric p53-Penetratin Peptide Binds to HDM-2 in a p53 Peptide-like Structure, Induces Selective Membrane-Pore Formation and Leads to Cancer Cell Lysis — Sarafraz-Yazdi et al. 2022
Reported benefits
- tumor cell necrosis in vitro and in xenograft models
- efficacy against chemotherapy-resistant cancers (preclinical)
Dosing protocols reported in the literature & community
These are protocols reported by compounding pharmacies, published trials, or self-experimentation communities — not a prescription. Start low, especially for anything new.
| Route | Reported protocol |
|---|---|
| Intravenous or intraperitoneal (mouse studies only) | Mouse models: ~50-100 μg/kg; NO human dosing exists or should be attempted. |
Side effects
- NO HUMAN DATA
- membrane-pore-forming mechanism could plausibly cause severe tissue damage if misapplied in vivo
Safety notes
Community & reddit notes (anecdotal — not clinical evidence)
Some longevity forums mistakenly categorize PNC27 as a life-extension peptide. It isn't — it's pure oncology research. Legitimate anecdotal human use essentially doesn't exist.
Related peptides
None listed.